Revvity, Inc., formerly known as PerkinElmer, Inc., operates in the healthcare sector. With a focus on diagnostics and life sciences, the company offers innovative solutions. Revvity's dedication to scientific breakthroughs positions it well for future growth. However, competitive pressures in its sectors remain a concern.
Revvity, Inc. demonstrates solid fundamental ratings, highlighting strengths in some financial metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 3 | |
| Return on Assets | 3 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 4 |
Examining scores over time provides insights into the company's financial trajectory.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| Current: | 3 | 4 | 3 | 3 | 2 | 1 | 4 |
| 2026-07-14 | 3 | 4 | 3 | 3 | 2 | 1 | 4 |
Analyst predictions reflect varying perspectives on the stock's potential trajectory.
| High | Low | Median | Consensus |
|---|---|---|---|
| 125 | 95 | 115 | 111.57 |
Analysts maintain a positive outlook, with a strong presence of 'Buy' recommendations.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 14 | |
| Sell | 0 | |
| Strong Sell | 0 |
Revvity, Inc. (RVTY) presents a balanced investment opportunity with robust scores in discounted cash flow and price-to-book ratios. The firm's revised outlook under its new brand name and strategy in diagnostics and life sciences portrays potential growth, although investor caution is advised due to market competition. Analysts largely view the stock favorably, suggesting optimism in its future performance, though acknowledging risks. Investors should consider both the opportunities for scientific advancement and the inherent challenges in the sector.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.